As more South Korean pharma companies seek to globalize and do cross-border license deals, licensing-related income and sales from overseas subsidiaries appear to be taking on greater weight in their financial performance.
The group reported largely solid earnings in calendar 2021, helped by multiple agreements and robust sales outside the country, as well as by
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?